Treatment of patients with rheumatoid arthritis (RA) is challenging due to clinical heterogeneity 2 and variability. Integration of RA synovial genome-scale transcriptomic profiling of different 3 patient cohorts can provide insights on the causal basis of drug responses. A normalized 4 compendium was built that consists of 256 RA synovial samples that cover an intersection of 5 11,769 genes from 11 datasets. Differentially expression genes (DEGs) that were identified in 6 three independent methods were fed into functional network analysis, with subsequent grouping 7 of the samples based on a non-negative matrix factorization method. Finally, we built a predictive 8 model for treatment response by using RA-relevant pathway activation scores and four machine 9 learning classification techniques. We identified 876 up-regulated DEGs including 24 known 10 genetic risk factors and 8 drug targets. DEG-based subgrouping revealed 3 distinct RA patient 11 clusters with distinct activity signatures for RA-relevant pathways. In the case of infliximab, we 12 constructed a classifier of drug response that was highly accurate with an AUC/AUPR of 0.92/0.86.
Introduction 1
Rheumatoid arthritis (RA) is a complex autoimmune disease involving a multitude of 2 environmental and genetic factors that exhibit nonlinear dynamic interactions (1). The disease is 3 characterized by chronic inflammation of the synovium, which results in irreversible damage to In this study, our aim is to elucidate the various transcriptional and signaling signatures of RA by 3 performing a comprehensive meta-analysis of the publicly available datasets that have been 4 published so far. We focus on synovial tissue samples to avoid the high false discovery rates 5 coming from blood samples. We have applied several preprocessing and normalization steps to 6 create a cohesive, homogenized compendium of genome-wide gene expression signatures for 7 downstream analysis. We used this compendium to separate expression-driven subgroup, 8 understand the key cellular components in each group and then use genes and pathways with high 9 information value that we have identified to create predictive models for drug responsiveness. 2 We used the keywords "Rheumatoid Arthritis", "Synovium or synovial tissue", "Transcriptomics 3 or microarray", "Dataset" in Google Scholar and PubMed to find relevant publications to the topic 4 of synovial gene signatures of patients with rheumatoid arthritis (Fig. 1) . We retrieved all 5 publications that were accompanied by high-throughput datasets (20 studies in total). From the 6 resulting set, we removed entries that had been duplicated and selected datasets measuring over 7 10,000 genes to secure the largest size of genes and samples. Since there was a trade-off between 8 the number of studies to include and the number of genes that are within the intersection from all 9 datasets, we optimized the product of the two by selecting the point where these two trends cross 10 ( Fig. S1) . The final RA sample count was 256, the osteoarthritis (OA) count 41, and 36 normal 11 (NC) samples were included as controls. Ultimately, the final RA compendium was constructed 12 out of 11 studies with a total of 333 samples, one per patient, covering 22,721 genes total (common 13 core of 11,769 genes).
Systematic search and data collection

15
Data normalization and removal of batch effects 16 For one-channel arrays, the image data was first imported and then the Robust Multi-array Average 17 (RMA) method was applied for a set of replicates for background correction, normalization, probe-18 set summarization. For dual-channel arrays, the image data were imported and background 19 correction was performed using normexp as it was shown to outperform other methods. Red and 20 green channels were separated and quantile-normalized for each set of replicates. The vectors for 21 the matrices were normalized using the quantile normalization method. Residual technical batch 22 effects arising due to heterogeneous data integration were corrected using the ComBat function 23 6 within the empirical Bayes package. Quality assurance and distribution bias was evaluated by 1 Principal Component Analysis (Fig. S2) .
3
The RA compendium 4 After preprocessing, the gene expression profiles have a significant reduction of systematic, 5 dataset-specific bias in comparison with the same dataset before normalization and batch 6 correction ( Fig. S2) . The resulting compendium has a gene size of 11,769 in 333 samples, 7 including 256 RA patients, 41 OA patients, and 36 normal controls. In 105 of the RA samples, 8 synovial tissue sampling was conducted before the start of certain drug: 11 for adalimumab 9 (ADLM), 62 for infliximab (IFXM), 8 for methotrexate (MTX), 12 for rituximab (RTXM), and 12 10 for tocilizumab (TOCM). For these patients, assessment of disease activity and response was 11 performed per the EULAR response criteria (9) 12-16 weeks after initiation of therapy: 32 were 12 good, 47 were moderate, and 26 were poor responders. Information on demographics and clinical 13 characteristics including age, sex, disease duration, and RF positive were not fully annotated for 14 each RA sample (Table S1 ).
16
Filtering of differentially expressed genes 17 In order to identify the differentially expressed genes (DEGs), we employed three widely-used 18 methods: (a) an empirical Bayesian method using the Benjamini and Hochberg procedure with a 19 significance threshold at an adjusted p-value < 0.05; (b) the Significance Analysis of Microarray 20 (SAM) method, with a significance threshold of false discovery rate FDR < 0.05; (c) the Rank 21 Products (RP) method with a significance threshold set at percentage of false prediction pfp < 0.05. The resulting list of DEGs is the intersection of the three individual DEGs sets for each method to 1 minimize the false discovery rate statistic.
3
Functional enrichment analysis 4 We performed functional enrichment analysis focusing on the up-regulated DEGs using the 5 Database for Annotation, Visualization, and Integrated Discovery (DAVID) software (10). Terms 6 were regarded significant if the p-value (EASE score) is lower than 0.05, the enrichment score 7 higher than 1.3, and the fold enrichment was larger than 1.5. Gene set enrichment analysis 10 Gene set enrichment analysis (GSEA) analysis was carried out using the GSEA software from the 11 Broad Institute to assess the overrepresentation of RA-related gene sets (11). The enrichment 12 results were visualized with the Enrichment Map format, where nodes represent gene-sets and 13 weighted links between the nodes represent an overlap score depending on the number of genes 14 two gene-sets share (Jaccard coefficient) (12). To intuitively identify redundancies between gene 15 sets, the nodes were connected if their contents overlap by more than 25%. Clusters map to one or 16 more functionally enriched groups, which were manually circled and assigned a label. 19 To assess the interconnectivity of DEGs in the RA synovium samples, we constructed a protein-20 protein network based on the interaction data obtained from public databases including BIOGRID 21 (13), HPRD (14), IntAct (15), Reactome (16), and STRING (17). In the network, nodes and edges 22 represent genes and functional or physical relationships between them, respectively. Graph theory 23 8 concepts such as degree, closeness, and betweenness were employed to assess the topology of this 1 network. Hub molecules were defined as the shared genes in top 10% with the highest rank in each 2 arm of the three centrality parameters (18). To obtain a genome-wide drug target prioritization, we applied the Heat Kernel Diffusion Ranking 6 approach (19). This method prioritizes the candidate genes by diffusing the differential expression 7 values of the candidate genes through the network based on the confidence scores of the 8 associations or interactions and is a powerful network-based machine learning approach to identify 9 putative drug targets. The diffusion process is formulated by using a Laplacian exponential 10 diffusion kernel and a score is computed by multiplying the differential expression values with the 11 heat kernel. Drug targets are assumed to get a high score since these genes tend to be the central Non-negative matrix factorization and determination of the optimal number of clusters 17 To classify the RA patients into subgroups based on their molecular signatures, we used the non-18 negative matrix factorization (NMF) method. NMF clustering is a powerful unsupervised approach 19 to identify the disease subtype or patient subgroup and discover biologically meaningful molecular 20 pattern (8,20). We applied the consensus NMF clustering method and initialized 100 times for 21 each rank k (range from 2 to 6), where k was a presumed number of subtypes in the dataset. For 22 each k, 100 matrix factorizations were used to classify each sample 100 times. The consensus 23 9 matrix was used to assess how consistently sample-pairs cluster together. We then computed the 1 cophenetic coefficients and silhouette scores for each k, to quantitatively assess global clustering 2 robustness across the consensus matrix. The maximum peak of the cophenetic coefficient and 3 silhouette score plots determined the optimal number of clusters (20). To confirm unsupervised 4 clustering results, we used t-distributed stochastic neighborhood embedding (t-SNE) (21), a 5 powerful dimensionality reduction method. The t-SNE method captures the variance in the data 6 by attempting to preserve the distances between data points from high to low dimensions without 7 any prior assumptions about the data distribution. Scoring of pathway activation 10 To quantify certain biological pathway activity, we calculated the gene expression z-scores (8,22).
18
Construction of protein-protein interaction network
11
Briefly, a Z-score is defined as the difference between the error-weighted mean of the expression 12 values of the genes in each pathway and the error-weighted mean of all genes in a sample after Supervised learning analyses for the prediction of drug responsiveness 21 We used Naïve Bayes (NB), Decision Trees (DT), k-Nearest-Neighbors (KNN), and Support
22
Vector Machines (SVM ) to create drug responsiveness predictors (24,25). Each binary SVM was 23 10 built using Gaussian Radial Basis Function (RBF) kernel and the Sigma hyperparameter was 1 determined from the estimation based upon the 0.1 and 0.9 quantiles of the samples. For soft 2 margins, the C parameter that achieved the best performance was in the range of 2 -4 to 2 7 . For 3 KNN, the k parameter was tuned in the range 2 to 20. All tuning hyperparameters were separately 4 determined for each bootstrapped training dataset.
5
To determine the optimal feature set that enables distinguishing 'good' from 'not good' responders 6 with the highest accuracy, we employed the wrapper feature selection method (25). The wrapper 7 method uses the classifier as a black box to rank different subsets of the features according to their 8 predictive power. In the wrapper method, a feature set is fed to the classifier and its performance 9 is scored and the feature set with the highest rank is selected as the optimal feature set. The 10 predictive power of each predictor was assessed through Receiver-Operator Characteristics (ROC) 11 and Precision-Recall (PR) curve (26). Data was separated into independent training and test sets 12 in a three-to-one sample-size ratio in a way of stratified random sampling. To make up for small 13 sample size and minimize the error, we constructed the pool of resampled dataset by applying 14 bootstrapping with 1000 iterations and subsequently applying a stratified 10-fold cross-validation 15 (CV) for each bootstrapped dataset (24,25). Tenfold CV measures the prediction performance in a 16 self-consistent way by systematically leaving out part of the dataset during the training process 17 and testing against those left-out subset of samples. Compared to the test on independent dataset, 18 CV has less bias and better predictive and generalization power. The predictive ability of the 19 models generated from all the approaches was tested by performing the CV test at all the ten 20 locations under study. Given the unequal numbers of trials in each class, balanced accuracy 21 formula was employed to calculate the accuracy (27). The baseline is estimated by random expectation based on the pre-determined ratio of each condition. In case of IFXM, a probability of 1 0.29 (18/62) for a "good" and 0.71 (44/62) for a "not good" responder was applied. For continuous distributed data, between-group comparisons were performed using the one-way 5 ANOVA, unpaired t-test or Mann-Whitney U test. Categorical or dichotomous variables were 6 compared using the chi-squared test or Fisher's exact test. To investigate the difference of pathway 7 activation score across the subgroups, we fitted the one-way ANOVA model using logistic 8 regression. All analyses were conducted in R (The R Project for Statistical Computing, www.r-9 project.org) and R packages used in the analysis and their references were summarized in the Table   10 S2. To get a list of RA-related DEGs, gene expression profiles of RA patients were compared with 3 samples from the OA and NC groups. We identified 2762 DEGs for RA versus OA, and 3087 4 DEGs for RA versus NC (Fig. 1) . Distribution of DEGs was assessed after the DEGs were divided 5 into up-and down-regulated groups ( Fig. 2A) . The number of up-regulated DEGs was 1486 for 6 RA versus OA and 1774 for RA versus NC. The intersection between two up-regulated DEG sets 7 was 876, which we considered as RA-unique ( Fig. 2A and Supplementary File S1). Enriched biological processes and protein-to-protein interaction network 10 Through GSEA, we performed a functional enrichment analysis where 206 gene ontology 11 processes were identified ( Fig. 2B and Fig. S3 ). As expected, immune-related biological processes interaction network of RA ( Fig. 2C) . We identified 3563 interactions among the 876 DEGs.
1 Thirty-one of DEGs were overlapped with RA genetic susceptibility loci previously discovered 2 (28) ( Fig. S5 ) and a total of 56 genes were ranked as hub molecules based on the centrality analysis. 3 The CD2, PTPRC (protein tyrosine phosphatase, receptor type C, also known as CD45), and to assess robustness of the clustering result, we computed the cophenetic coefficient and silhouette 23 14 score for different numbers of clusters from 2 to 6, where we found that 3 clusters are the optimal 1 representation of the data (Fig. 3A, Fig. S7, and Methods) . Segregation of RA subgroups was also 2 reproduced by t-SNE analysis and principal component analysis (Fig. 3B) . To identify 3 characteristic molecular signaling pathways enriched in each cluster, we performed functional 4 enrichment analyses for the predicted genes of each cluster (Fig. 3C) . Nine enriched pathways list not their expression levels, missing gene sets, and bias towards well-studied genes, and 12 dropouts of some genes during combining the datasets. Thus, to better understand the differences 13 among the three clusters, we analyzed the activation of individual pathways with adding six more 14 pathways that are known to be associated with RA (30,32,33): transforming growth factor (TGF)-15 -, vascular endothelial growth factor (VEGF)-, Wnt-, B cell receptor (BCR)-, NFB-, PI3K-AKT 16 (Fig. 4) . As shown in the chord diagram, these pathways are strongly connected, with only TGF-, 17 P53-, and Wnt signaling pathways more isolated than others (less shared DEGs). Especially TGF-18 and Wnt, have an opposite trend in their DEG expression (higher in cluster 1, mid in cluster 2 and 19 low in cluster 3), which is the opposite of the trend we observe in most of the other pathways ( Fig.   20   4 and Fig. S8 ). P53 signaling pathways shared fewer genes with other pathways but strongly 21 correlated with BCR-, chemokine-, Fc  RI-, TCR-, TLR-, and TNF signaling pathways. 1 clusters, all clusters exhibited one of the two trends in a statistically significant manner (P<0.05 in 2 all cases) and in accordance with the observation through DEG-driven enrichment (all cases except 3 TNF). It was found that IFN-related processes were enriched in GSEA and this was reproduced in 4 the precedent studies (5,34-37). Since KEGG database did not provide IFN pathways data, we 5 imported data on gene set of IFN pathways from the Reactome database. Levels of activation score 6 of Type I and II IFN pathways were significantly different across the clusters (all P<0.001) and 7 showed a tendency to increase from cluster 1 to 3 (Fig. S9) . Compared with RA cluster 2 and 3, 8 RA cluster 1 had moderate activation scores for most of the proinflammatory signaling pathways 9 but high for PI3K-AKT-, TGF-and Wnt signaling pathways, which are principally involved in 10 synovial proliferation and tissue remodeling (38). RA cluster 2 and 3 showed comparable activities 11 for most of the proinflammatory pathways. More active in RA cluster 2 were the P53-and PI3K-12 AKT signaling pathways, which were reported to play a role in regulating apoptosis of 13 synoviocytes or macrophages (39,40). In RA cluster 3, TCR-, Jak-STAT-, and NFB signaling 14 pathways were remarkable and it is noteworthy that IFN signaling pathways were most scored.
15
Cellular processes affected by these pathways are in agreement with the DEG-driven enriched GO 16 terms in each cluster (Fig. S10) . This result indicates that there exist RA subgroups representing a 17 distinct mode of inflammation deflected toward a certain combination of signaling pathways 18 (Table S3 ). To prioritize the drug candidate targets, we ranked the DEGs using the Heat Kernel features based on the provided information. There was no difference in gender ratio, age 23 16 distribution, and tissue sampling method across the subgroups (P > 0.10 in all cases, see Fig. S11 ). 1 Because data on the disease duration, activity, and RF positive were not provided individually for 2 each sample, we compared two distinctively opposing datasets from compendium: the first 3 (GSE45867) includes naïve, untreated RA patients with disease duration of <1 year, moderate 4 disease activity and with arthroscopic needle biopsy performed before MTX or TCZM therapy 5 (41). The second (GSE21537) is a cohort of the long-standing RA patients with high disease 6 activity who had failed at least two DMARDs (including MTX) and did arthroscopic needle biopsy 7 before IFXM therapy (42). Disease duration and activity were significantly longer and higher in 8 the latter dataset (all P < 0.001) while there was no difference in age, gender, and RF positive 9 between two datasets (all P > 0.10). Distribution of 3 subgroups did not differ between two datasets 10 (P = 0.8664) ( Fig. S11) , indicating gene expression pattern by 3 subgroups have little direct 11 relevance to disease duration and activity. Towards a predictor of drug response 14 For 105 RA samples that we had drug effectiveness data, we tested the hypothesis that there is an 15 association between drug responsiveness and cluster membership. Out of the 5 drugs that we had 16 data on (ADLM, IFXM, MTX, RTXM, and TOCM) we were not able to identify any such 17 association (Fig. S12) . Cluster 1 patients had an encouraging response to TOCM but at a low 18 statistical significance level (p-value equal to 0.082). In addition to the intricacy of the pertinent 19 pathways, the small size of samples treated by the specific drug, and their potential heterogeneity 20 make the association between drug responsiveness and RA clusters difficult.
21
Since the differential expression of genes and pathways is at a higher resolution than general 22 clustering signatures, we tested whether drug response can be predicted by using such features. 23 We focused on the patients that were treated with IFXM due to the larger sample size (n=62). To 1 test this hypothesis, we applied outcome to a binary classification (labels of "good" and "not good" 2 responder) and tried two approaches: pathway-driven and DEG-driven models. Note that PCA 3 analysis does not reveal separating distributions between the "good" and "not good" responders 4 both for pathway activation score and DEG values (Fig. S13) . 5 As features, we used the 17 pathways that are represented by continuous variables through their 6 activation scores (refer to the pathway activation score for each pathway in the Supplementary 7 File S2). To reduce the number of dimensions we performed feature selection through recursive 8 elimination ( Table S4 ). Based on those results made a predictive model using 4 supervised 9 machine learning methods (NB, DT, KNN, and SVM) for selected key pathway scores and 10 calculated the performance. All models outperformed the baseline (all P < 0.001) (Fig. 5A, left   11 plot) and SVM, the best performing model, had an average performance AUC/AUPR of 0.87/0.78 12 (all P < 0.001) (Fig. 5A, middle and right plots) . The selected key predictors for SVM model were 13 NFB-, FcRI-, TCR-, and TNF signaling pathways. Next, models based on expression values of 14 DEG were fit in order to sort out the informative genes and compare their performance with 15 pathway-driven models. DEG-driven models showed superior performance as compared with 16 pathway-driven models (Fig. 5B, left plot) . The overall AUC of the ROC curves exceeds 0.85 ( Fig.   17 5B, middle and right plots). SVM showed the best performance AUC/AUPR of 0.92/0.86 and with 18 the HMMR, PRPF4B, EVI2A, RAB27A, MALT1, SNX6, and IFIH1 genes as features. The 19 expression of these genes provide a distinct signature between two different outcomes (P < 0.05 20 in all cases, see Fig. S14 ). However, they are more suitable to understand the mechanism and response to RA, since blood-11 derived samples are a distant and hence more noisy proxy to the disease, with known quality issues 12 (4-6). Moreover, to refine the RA-unique genes, we compared RA samples with two control sets 13 (OA and NC groups) and adopted the DEGs shared by three independent methods. We found that 14 24 of the DEGs are the known RA-associated genetic loci and take a central position in the synovial 15 network. Since functional implications of risk allele were often obscure, it would be helpful to 16 elucidate the biological mechanisms in which risk alleles operate. STAT1, a transcription factor 17 downstream of IFN signaling pathway, highlighted as a key molecule in the previous reports 18 (35,43), was found to be one of the hub genes. Other hub genes, such as JAK2, SYK, and BTK are 19 small molecules that have increasingly drawn attention as novel therapeutic targets following the 20 cytokine-targeting biologics (30). In contrast, molecules such as TNF receptor molecules, CTLA4, 21 IL6R, and MS4A1 were located at the functional periphery of the network although drugs against 22 these molecules are widely used in clinical practice. Moreover, these molecules were placed farther 23 19 from RA-associated genes than JAK2 and SYK in the network, inferring part of their less potent 1 efficacy in active RA. This was in good harmony with a recent clinical trial that baricitinib, an 2 inhibitor of the Janus kinases JAK1 and JAK2, showed a stronger therapeutic effect as compared 3 with ADLM, a TNF inhibitor (44). signatures in a subset of RA patients and its substantial similarity to viral infection (5,34-37,46) 10 and one reported that the type I IFN signature negatively predicts the clinical response to rituximab 11 treatment in patients with RA (34). Here, our results suggest that such a probable link between the 12 IFN signature and the anti-viral response may exist (46). 13 Interestingly, we were able to identify three distinct subgroups through NMF analysis of the RA (38). RA clusters 2 and 3 showed a strong disposition for proinflammatory signaling pathways 23 20 (Chemokine-, TNF-, TLR-and VEGF signaling pathways). Apoptosis-related pathways (P53-and 1 PI3K-AKT signaling pathway) were much prominent in RA cluster 2 (39,40), while BCR-, Jak-2 STAT-, NFB-, and TCR signaling pathways were stronger in RA cluster 3. It is known that 3 synoviocytes are the main culprit of invasive synovium and quantitative and qualitative activities 4 of synovial macrophage reflect therapeutic efficacy (48,49). They add to the cellular resistance to 5 apoptosis and increase of the potential for proliferation, hence they contribute to the progression 6 and perpetuation of destructive joint inflammation. Therefore, we speculate that an aggressive 7 suppression of pro-inflammatory signals would be better pertinent to RA cluster 3, while 8 therapeutic strategies to control propagation and survival of synoviocytes and macrophages 9 together with anti-inflammatory treatment should be considered in RA cluster 1 and 2 (50) ( Table   10   S3 ). This insight, together with the candidate gene targets for drug development that we have 11 identified in each cluster, may provide good starting points for delivering precision and 12 personalized treatment. 13 Machine learning has become ubiquitous and indispensable for solving complex problems in most 14 sciences (51). Since the problem of unresolved heterogeneity is prevalent to medicine, the same There are some limitations to be addressed in this study. First, removal of batch effects is not ideal 10 which adds to the noise in the compendium. Second, we did not fully address the association of 11 RA subgroup with clinical factors including age, sex, disease duration, and RF positive due to lack 12 of complete annotation for each RA sample. Third, a limited number of samples were treated with 13 other drugs except for IFXM precluded us from making a predictive model. In general, more meta-14 data would be desired, although this is to be expected as these studies were performed in different 15 clinical environments, with different procedures and goals, which did not include their aggregation 16 to a single compendium and application of advanced machine learning techniques. In the future, 17 we anticipate that the construction of datasets with sufficient metadata for machine learning 18 analysis would enable critical insights and may lead to novel drug targets for RA treatment. 
Discussion
